OTC Markets OTCQB - Delayed Quote USD

Nymox Pharmaceutical Corporation (NYMXF)

Compare
0.0800
-0.0300
(-27.27%)
At close: January 24 at 11:02:10 AM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
-5.0000
--
--
--
5.0000
Cost of Revenue
--
--
--
--
4.0000
Gross Profit
--
--
--
--
1.0000
Operating Expense
8,345.0000
8,350.0000
6,652.0000
12,504.0000
11,721.0000
Operating Income
-8,350.0000
-8,350.0000
-6,652.0000
-12,504.0000
-11,720.0000
Net Non Operating Interest Income Expense
-162.0000
-55.0000
-42.0000
-31.0000
-15.0000
Other Income Expense
--
-439.0000
118.0000
-2.0000
-3.0000
Pretax Income
-8,946.0000
-8,844.0000
-6,576.0000
-12,537.0000
-11,738.0000
Net Income Common Stockholders
-8,946.0000
-8,844.0000
-6,576.0000
-12,537.0000
-11,738.0000
Diluted NI Available to Com Stockholders
-8,946.0000
-8,844.0000
-6,576.0000
-12,537.0000
-11,738.0000
Basic EPS
-0.10
--
-0.07
-0.15
-0.16
Diluted EPS
-0.10
--
-0.07
-0.15
-0.16
Basic Average Shares
93,102.4420
--
89,383.0000
81,976.0000
73,823.0000
Diluted Average Shares
93,102.4420
--
89,383.0000
81,976.0000
73,823.0000
Total Operating Income as Reported
-8,348.0000
-8,350.0000
-6,652.0000
-12,504.0000
-11,720.0000
Total Expenses
8,345.0000
8,350.0000
6,652.0000
12,504.0000
11,725.0000
Net Income from Continuing & Discontinued Operation
-8,946.0000
-8,844.0000
-6,576.0000
-12,537.0000
-11,738.0000
Normalized Income
-8,507.0000
-8,405.0000
-6,581.0000
-12,535.0000
-11,735.0000
Interest Income
--
6.0000
1.0000
8.0000
27.0000
Interest Expense
--
61.0000
43.0000
39.0000
42.0000
Net Interest Income
-162.0000
-55.0000
-42.0000
-31.0000
-15.0000
EBIT
-8,783.0000
-8,783.0000
-6,533.0000
-12,498.0000
-11,696.0000
EBITDA
-8,771.0000
-8,614.0000
-6,284.0000
-12,244.0000
-11,429.0000
Reconciled Cost of Revenue
--
--
--
--
4.0000
Reconciled Depreciation
12.0000
169.0000
249.0000
254.0000
267.0000
Net Income from Continuing Operation Net Minority Interest
-8,946.0000
-8,844.0000
-6,576.0000
-12,537.0000
-11,738.0000
Total Unusual Items Excluding Goodwill
-439.0000
-439.0000
5.0000
-2.0000
-3.0000
Total Unusual Items
-439.0000
-439.0000
5.0000
-2.0000
-3.0000
Normalized EBITDA
-8,332.0000
-8,175.0000
-6,289.0000
-12,242.0000
-11,426.0000
12/31/2020 - 11/26/1997

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MDNAF Medicenna Therapeutics Corp.
0.9380
+0.05%
 
DYAI Dyadic International, Inc.
1.4700
-4.55%
 
PHRM.CN PharmaTher Holdings Ltd.
0.2300
+4.55%
 
CLGN CollPlant Biotechnologies Ltd.
3.7100
-6.08%
 
NGENF NervGen Pharma Corp.
1.9600
-1.01%
 
BCDA BioCardia, Inc.
2.1900
+0.46%
 
ONCO.CN Onco-Innova
2.5500
+15.91%
 
SABS SAB Biotherapeutics, Inc.
4.1000
+12.48%
 
ANNX Annexon, Inc.
4.1300
-2.59%
 
MGNX MacroGenics, Inc.
3.2300
+2.22%